Organization Profile

You just read:

Europace Publishes Data Supporting Use Of BRINAVESS™ (Vernakalant) As A First Line Agent For Pharmacological Cardioversion Of Atrial Fibrillation

News provided by

Cardiome Pharma Corp.

Nov 21, 2013, 07:45 ET